© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats
aDisease Group Cardiovascular Diseases, Aventis Pharma Deutschland GmbH, Building H 821, D-65926, Frankfurt am Main, Germany
bDSE Pathology, Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany
cGroup Biomarkers, Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany
dDrug Metabolism and Pharmacokinetics, Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany
*Corresponding author. Tel.: +49-69-3051-3391; fax: +49-69-3051-6394. Email address: stefan.schaefer{at}aventis.com
Background: Blocking the renin–angiotensin system is an established therapeutic principle in diabetic nephropathy. We investigated whether inhibition of both neutral endopeptidase and ACE (vasopeptidase inhibition) can prevent functional and morphological features of nephropathy in the Zucker diabetic fatty (ZDF) rat, an animal model of type II diabetes. Methods: Homozygous (fa/fa) ZDF rats (each n = 15) aged 10 weeks were treated with placebo, ramipril (1 mg/kg/day in drinking water), or the vasopeptidase inhibitor AVE7688 (45 mg/kg/day in chow). Metabolic parameters and renal function (metabolic cages) were assessed at baseline (age 10 weeks), and at age 17, 27, and 37 weeks. Twenty heterozygous animals (fa/–) served as lean, nondiabetic controls. At age 37 weeks, the animals were sacrificed and the kidneys analyzed histopathologically. Results: Overt diabetes mellitus (blood glucose >20 mmol/l) was established at age 17 weeks in all homozygous ZDF rats. In the placebo group, urinary protein excretion increased progressively from 8±1 (baseline) to 342±56 mg/kg/day (week 37) whereas diabetes and proteinuria were absent in the lean control group. Ramipril tended to reduce albuminuria and morphological damage (p = ns) but AVE7688 virtually prevented albuminuria (33±12 mg/kg/day, p<0.05 vs. ZDF placebo) and drastically reduced the incidence and severity of glomerulosclerosis and tubulointerstitial damage. Conclusions: In ZDF rats, development of diabetes mellitus is accompanied by functional and morphological kidney damage that resembles human diabetic nephropathy. Diabetic nephropathy can be prevented by chronic vasopeptidase inhibition.
KEYWORDS Zucker diabetic fatty rat; Diabetic nephropathy; Angiotensin-converting enzyme inhibitor; Vasopeptidase inhibitor
Time for primary review 21 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Niehof and J. Borlak HNF4{alpha} and the Ca-Channel TRPC1 Are Novel Disease Candidate Genes in Diabetic Nephropathy Diabetes, April 1, 2008; 57(4): 1069 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Linz, S. Schafer, F. Afkham, M. Gerl, H.-L. Schmidts, and H. Rutten Vasopeptidase Inhibition Prevents Target Organ Damage and Improves Survival in Spontaneously Hypertensive Rats Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 155 - 161. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Schafer, J. Huber, C. Wihler, H. Rutten, A. E. Busch, and W. Linz Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N{varepsilon}-(carboxymethyl) lysine Eur J Heart Fail, January 1, 2006; 8(1): 2 - 6. [Abstract] [Full Text] [PDF]
|
|